Aug 6, 2026, 7:32 AM EDT · 1 month ago PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Aug 6, 2026, 7:30 AM EDT · 1 month ago PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
May 21, 2026, 7:00 AM EDT · 4 months ago PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program
May 12, 2026, 4:05 PM EDT · 4 months ago PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Mar 31, 2026, 10:33 AM EDT · 6 months ago PepGen Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Mar 30, 2026, 4:05 PM EDT · 6 months ago PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data
Mar 4, 2026, 4:56 PM EST · 7 months ago US FDA puts partial clinical hold on PepGen's muscle disease drug trial
2026-03-04T21:20:06.000Z · 7 months ago PepGen announce FDA placed partial clinical hold on Phase 2 trial of PGN-EDODM1
Mar 4, 2026, 4:05 PM EST · 7 months ago PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights
Mar 3, 2026, 7:00 AM EST · 7 months ago PepGen to Participate in the Leerink Global Healthcare Conference
Dec 9, 2025, 7:00 AM EST · 9 months ago PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Business and Legal Officer
Dec 8, 2025, 7:00 AM EST · 9 months ago PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer
Nov 12, 2025, 7:05 AM EST · 10 months ago PepGen Announces Issuance of U.S. Patent for Proprietary PGN-EDODM1 Molecule
Nov 12, 2025, 7:00 AM EST · 10 months ago PepGen Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
Oct 2, 2025, 7:00 AM EDT · 1 year ago PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle Society
Sep 26, 2025, 4:01 PM EDT · 1 year ago PepGen Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
Sep 24, 2025, 4:16 PM EDT · 1 year ago PepGen Announces Highest Mean Splicing Correction Reported in DM1 Patients
Aug 7, 2025, 8:00 AM EDT · 1 year ago PepGen Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
Jun 10, 2025, 10:44 AM EDT · 1 year ago PEPGEN INC. (NASDAQ: PEPG) INVESTOR ALERT Investors With Large Losses in PepGen Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
May 28, 2025, 6:21 PM EDT · 1 year ago PepGen to discontinue development of experimental Duchenne therapy; shares drop
May 28, 2025, 4:05 PM EDT · 1 year ago PepGen to Focus on Development of Promising DM1 Program Following 10 mg/kg PGN-EDO51 Update
May 20, 2025, 7:00 AM EDT · 1 year ago PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer
May 8, 2025, 8:00 AM EDT · 1 year ago PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights